Merck Wages Separate Press Battle Outside Of Aussie Vioxx Court
This article was originally published in PharmAsia News
U.S.-based Merck apparently is waging a public relations war in Australia to offset fallout from a trial in federal court over its recalled Vioxx (rofecoxib) drug to treat arthritis. The company has a crisis-management team that attends the daily trial to observe journalists in and out of court. Team members monitor what reporters write, give them off-the-record information stressing Merck's own interpretation of events and sometimes harassing them about their stories. The team, guided by a U.S.-based spokeswoman, also writes almost daily letters to editors to stress Merck's case, all activity considered by one Australian attorney as highly unusual. (Click here for more
You may also be interested in...
CV Defense, the second launch in the firm’s new immune-support line (without cannabidiol), is built around palmitoylethanolamide and other nutrients and botanicals to “optimize immune response.” CV Sciences touts the immunity range as complementary to its PlusCBD brand, which is in the process of rolling out dozens of new products in updated packaging.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
US, EU and Canadian authorities recently discussed their approaches to rolling reviews of CMC applications for coronavirus vaccines.